Riskpilot← Back to searchSign inGet full accessDERMALYS AS
ASActiveOrg 919415517John Strandruds Vei 16, 1360 FornebuWholesale of perfume and cosmetics · NACE 4645Est. 20173 employees
Revenue 2024
NOK 2,9M
+70% vs 2023
EBITDA margin
-210.5%
-18% vs 2023
Equity ratio
-193.0%
Financial strength
Net profit 2024
NOK -8,6M
-83% vs 2023
| Revenue | NOK 2,9M | +70% |
| EBITDA | NOK -6,1M | -18% |
| Net profit | NOK -8,6M | -83% |
| Total assets | NOK 4,2M | -46% |
| Equity | NOK -8,1M | -1479% |
| Employees | 3 | — |
Legal name
DERMALYS AS
Org number
919415517
Legal form
Aksjeselskap
NACE code
4645 · Wholesale of perfume and cosmetics
Founded
15. august 2017
Share capital
NOK 58 170
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Import og distribusjon av kosmetikk. Kosmetiske behandlinger.
Address
John Strandruds Vei 16, 1360 Fornebu
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 55 | 924 | 1 391 | 1 238 | 1 168 | 996 | 1 710 | 2 899 |
| Staff expenses | −0 | −0 | −154 | −340 | −512 | −1 165 | −2 811 | −3 362 |
| EBITDA | −141 | 187 | 13 | 42 | −330 | −1 752 | −5 183 | −6 104 |
| Depreciation & amort. | −0 | −0 | −0 | −4 | −38 | −77 | −346 | −417 |
| EBIT | −141 | 187 | 13 | 37 | −368 | −1 828 | −5 528 | −6 521 |
| Net financials | 0 | 0 | −2 | −10 | −10 | −65 | −352 | −482 |
| Profit before tax | −141 | 187 | 10 | 27 | −377 | −1 893 | −5 880 | −7 003 |
| Tax | −34 | 44 | 3 | 6 | −83 | −414 | −1 148 | 1 645 |
| Net profit | −107 | 144 | 7 | 21 | −294 | −1 479 | −4 731 | −8 648 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 314 | 401 | 435 | 1 919 | 1 841 | 4 324 | 7 670 | 4 178 |
| Equity | −83 | 61 | 68 | 89 | 295 | −1 184 | 585 | −8 064 |
| Long-term debt | 0 | 0 | 0 | 1 650 | 1 260 | 4 200 | 4 011 | 9 932 |
| Short-term debt | 397 | 340 | 367 | 179 | 286 | 1 308 | 3 074 | 2 310 |
| Total debt | 397 | 340 | 367 | 1 829 | 1 546 | 5 508 | 7 085 | 12 242 |
EBITDA margin
-210.5%
This company
15.8%
Market median
-1432% vs market
20172024
Equity ratio
-193.0%
This company
38.2%
Market median
-605% vs market
20172024
Return on equity
-864840000.0%
This company
18.4%
Market median
-4700217491% vs market
20172024
Net profit margin
-298.3%
This company
8.1%
Market median
-3783% vs market
20172024
Asset turnover
0.69×
This company
1.12×
Market median
-38% vs market
20172024
Debt / equity
1.52×
This company
0.62×
Market median
-145% vs market
20172024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-07-13 – 2017-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
EM Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
JS Chief Executive Officer | Chief Executive Officer | 2018 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2024 | — | — | |
| Chairman | 2024 | — | — | |
| Chairman | 2025 | — | — | |
| Board of Directors | 2024 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Red Mit As | Company | 51.0% | 51.0% | 2024 |
Puigbanon As | Company | 38.7% | 38.7% | 2024 |
| Individual | 10.0% | 10.0% | 2022 | |
| Individual | 5.3% | 5.3% | 2024 | |
Rev Invest As | Company | 5.0% | 5.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
DERMALYS AS 
APELO ASBoard members of DERMALYS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Elena Marta Puig Syversen | Chief Executive Officer | 0 companies |
| Joaquin Samper Banon | Chief Executive Officer | 0 companies |
| Ole Richard Anfinnsen | Board of Directors | 0 companies |
| Jack Helge Holand | Chairman | 0 companies |
| Reinert Engelschiøn Vigtel | Chairman | 0 companies |
| Lisbet Oddveig Brekke | Board of Directors | 0 companies |